Mostrando 10 resultados de: 11
Filtros aplicados
Publisher
Seminars in Oncology(2)
BJGP Open(1)
Bionatura(1)
Cancer Biology and Therapy(1)
Cancer Biotherapy and Radiopharmaceuticals(1)
Área temáticas
Enfermedades(10)
Farmacología y terapéutica(10)
Medicina y salud(2)
Ginecología, obstetricia, pediatría, geriatría(1)
Problemas sociales y servicios a grupos(1)
Origen
scopus(11)
Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
ArticleAbstract: Background: CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shownPalabras claves:immune checkpoint inhibitor, immunotherapy, lung cancer, Non-small cell lung cancer, VaccineAutores:Attwood K., Cedeno C., Cinquino A., Dai T., Dozier A., Dy G.K., Ernstoff M., Evans R., Fisher D.T., Fountzilas C., Groman A., Hutson A., Johnson C., Lage Davila A., Lee K., Leon K., Luaces P.L.o., Mazorra Z., Mesa C., Muhitch J., Opyrchal M., Puzanov I., Reid M., Saavedra Hernández D., Santos-Morales O., Tania Crombet, Wallace P.K.Fuentes:scopusCIMAvax-EGF: A new therapeutic vaccine for advanced non-small cell lung cancer patients
ReviewAbstract: Lung cancer is the common fatal illness with the highest incidence and mortality globally. EpidermalPalabras claves:cancer vaccine, CIMAvax-EGF, Clinical trial, immunotherapy, Non-small cell lung cancerAutores:Saavedra Hernández D., Tania CrombetFuentes:scopusCIMAvax-EGF: Toward long-term survival of advanced NSCLC
ReviewAbstract: Lung cancer remains one of the leading causes of cancer-related deaths. Non–small cell lung cancer (Palabras claves:cancer vaccine, CIMAvax-EGF, Clinical trial, EGF, Epidermal growth factor receptor, immunotherapy, non–small cell lung cancerAutores:Camilo Rodríguez, Carmen Elena Viada, Lage Davila A., Mazorra Z., Neninger Vinageras E., Saavedra Hernández D., Tania CrombetFuentes:scopusEvaluation of CIMAvaxEGF for the treatment of lung cancer: Meta-analysis of controlled clinical trials
ArticleAbstract: CIMAvaxEGF is a therapeutic cancer vaccine developed in Cuba and fully licensed in the country for uPalabras claves:EGF receptor, Epidermal growth factor, immunotherapy, Of non-small cell lung cancer vaccine therapy, Oncology vaccinesAutores:Aliuska Frías, Ballesteros J., Bárbara Wilkinson, Camilo Rodríguez, Carmen Elena Viada, Mabel Álvarez, Martha M. Fors-López, Neninger Vinageras E., Quintero J., Robaina M., Tania CrombetFuentes:scopusDifferential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer
ArticleAbstract: Background: Progress in immunotherapy has revolutionized the treatment landscape for advanced lung cPalabras claves:immunotherapy, long-term survival, non–small cell lung cancer, survival mixture modelsAutores:Alfonso S., Carmen Elena Viada, Lage Davila A., Luaces P.L.o., Muchene L., Neninger Vinageras E., Rodríguez P.C., Sánchez L., Shkedy Z., Tania CrombetFuentes:scopusMulticentre oncology clinical trials in primary health care in Cuba: evaluation of programme implementation in Villa Clara Province, 2010–2020
ArticleAbstract: Background: The Center of Molecular Immunology of Cuba has developed a programme for the conductingPalabras claves:clinical trials, General practitioners, immunotherapy, neoplasms, Oncology, Primary Health Care, primary healthcareAutores:Artiles M., Cepeda M., Crespo J.C., de la Barca N.d.C., González A., Granela M.C., Lage Davila A., Lorenzo G., Marrero R., Méndez R., Nieto L., Norvel M., Ortiz R.A., Rodríguez M., Sánchez L., Tania Crombet, Toledo E., Torres O.Fuentes:scopusNimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck
ArticleAbstract: The prognosis of patients with advanced head and neck cancer remain dismal. For this tumor type, elePalabras claves:Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, nimotuzumab, Squamous cell carcinoma of the head and neck, Targeted therapyAutores:Alert J., Bahi R.D.C., Bárbara Wilkinson, Bilbao M.A., Carmen Elena Viada, De Armas E.L., Frómeta M., Galainena J.J., Gracias E., Iznaga N., Leonard I., Luaces P.L.o., Muchuli C.R., Mulén B., Mullens V., Pérez K., Pineda I., Rivero T.C., Rodríguez E., Rodríguez M.O., Tania Crombet, Torres O., Vinageras E.N.Fuentes:scopusImmunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients
ArticleAbstract: Increased levels of NeuGc-containing gangliosides have been described in human breast cancer. A contPalabras claves:Breast Cancer, cancer vaccine, Clinical trial, Ganglioside, immunotherapy, NeuGcGM3, patientsAutores:Cardoso J., Carmen Elena Viada, Carr A., De La Torre A.V., Díaz R., Fernandez L.E., Macías A.E., Marinello P., Mazorra Z., Mulens V., O'Farrill M., Pérez R., Rodríguez R., Saurez G., Tania CrombetFuentes:scopusImmunotherapy for Transforming Advanced Cancer into a Chronic Disease: How Far Are We?
Book PartAbstract: For chronic diseases medical success does not mean cure, but long-term control, improved quality ofPalabras claves:antibody, Cáncer, Cancer Vaccines, Chronicity, Clinical trial, immunotherapyAutores:Lage Davila A., Tania CrombetFuentes:scopusPhase I clinical evaluation of a neutralizing monoclonal antibody against Epidermal Growth Factor Receptor
ArticleAbstract: Ior egf/r3 a neutralizing monoclonal antibody (mAb) against Epidermal Growth Factor Receptor (EGFR)Palabras claves:Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, Phase I clinical trial, Tyrosine kinase inhibitorsAutores:Catalaá M., Fernández E., Iznaga N., Neninger Vinageras E., Peérez R., Ramos M., Rodríguez N., Tania Crombet, Torres O.Fuentes:scopus